SCHEMBL1890589

SCHEMBL1890589

Cc1ccc(C(=O)Cl)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
CSNK2A1 P68400 1/20 0.50
TRPA1 O75762 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
PLG P00747 3/20 0.45
KLK1 P06870 2/20 0.45
KLK6 Q92876 2/20 0.45
CES2 O00748 1/20 0.45
MAPT P10636 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5958350 0.83 CSNK2A1 (0.67) NPC1RAB9ACSNK2A1TRPA1MAPT
SCHEMBL302204 0.82 CSNK2A1 (0.48) NPC1RAB9ACSNK2A1MAPTKDM4E
SCHEMBL1758035 0.82 NPC1 (0.56) NPC1RAB9ACSNK2A1TRPA1TAS1R3
SCHEMBL30578000 0.82 NPC1 (0.56) NPC1RAB9ACSNK2A1TRPA1TAS1R3
SCHEMBL108320 0.80 NFE2L2 (0.47) NPC1RAB9ACSNK2A1TAS1R3TAS1R1
SCHEMBL6856523 0.80 NPC1 (0.55) NPC1RAB9ACSNK2A1TRPA1TAS1R3
SCHEMBL29495480 0.80 ALDH1A1 (0.57) NPC1RAB9ACSNK2A1TRPA1TAS1R3
SCHEMBL760290 0.80 ALDH1A1 (0.57) NPC1RAB9ACSNK2A1TRPA1TAS1R3
SCHEMBL168869 0.80 CSNK2A1 (0.69) NPC1RAB9ACSNK2A1TRPA1MAPT
SCHEMBL8906715 0.79 CES2 (0.70) CES2MAPTALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111138376-A 3, 5-disubstituted phenyl-1, 2, 4-oxadiazole derivative and preparation method and application thereof 中山大学 2020-05-12 CN disclosed
CN-103992336-B Oxa-or thia evodiamine anti-tumor derivant and preparation method thereof 中国人民解放军第二军医大学 2017-01-04 CN disclosed
CN-103992336-A Oxa- or thio-evodiamine anti-tumor derivatives and preparation method thereof UNIV PLA 2ND MILITARY MEDICAL 2014-08-20 CN disclosed
US-20110117649-A1 Catalytic enantioselective synthesis of flavanones and chromanones NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-05-19 US disclosed
US-7851640-B2 Catalytic enantioselective synthesis of flavanones and chromanones NORTHWESTERN UNIVERSITY (US) 2010-12-14 US disclosed
US-20090259055-A1 Catalytic enantioselective synthesis of flavanones and chromanones NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-10-15 US disclosed
WO-2009108392-A2 CATALYTIC ENANTIOSELECTIVE SYNTHESIS OF FLAVANONES AND CHROMANES NORTHWESTERN UNIVERSITY (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259055-A1 Catalytic enantioselective synthesis of flavanones and chromanones RNGTT, CDK20, TBXAS1 NPC1 4587/4885RAB9A 3477/4885CSNK2A1 3000/4885
US-20110117649-A1 Catalytic enantioselective synthesis of flavanones and chromanones RNGTT, CDK20, TBXAS1 NPC1 4587/4885RAB9A 3477/4885CSNK2A1 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.